| 1 | Psychiatry Clin. Neurosci. 2004 Oct 58: 579-81 |
|---|---|
| PMID | 15482592 |
| Title | Novel missense polymorphism in the regulator of G-protein signaling 10 gene: analysis of association with schizophrenia. |
| Abstract | Dysfunction of neuronal signal transduction via G-protein has previously been speculated to be involved in the pathophysiology of schizophrenia. Regulator of G-protein signaling (RGS) is a protein that acts as a GTPase-activator for Galpha protein. A total of 33 Japanese patients with schizophrenia were screened for mutations in the coding region of the RGS10 gene, and a novel missense polymorphism (Val38Met) in the RGS domain was detected. A case-control study did not reveal a significant association between this polymorphism and schizophrenia. The results do not provide evidence that the RGS10 gene is involved in biological vulnerability to schizophrenia. |
| SCZ Keywords | schizophrenia, schizophrenic |
| 2 | Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2005 Sep 61: 831-3 |
| PMID | 16511171 |
| Title | Crystallization and preliminary X-ray crystallographic analysis of human RGS10 complexed with Galphai3. |
| Abstract | G-protein-coupled receptors, which are major targets for drug discovery, play a major role in diverse physiological processes by relating changes in the extracellular environment to intracellular functions via activation of heterotrimeric G-proteins. However, G-protein activity is also modulated by a family of proteins called regulators of G-protein signalling (RGS), which are classified into six subfamilies. RGS10 belongs to the subgroup D/R12 and is known to act specifically on activated forms of three Galpha proteins (Galphai3, Galphaz and Galphao but not Galphas). It is abundantly expressed in brain and immune tissues and has been implicated in the pathophysiology of schizophrenia. The RGS domain of RGS10 was cloned, purified, complexed with human Galphai3 and crystallized. The crystals containing both RGS and Galphai3 belong to space group P4(3)2(1)2 (or P4(1)2(1)2), with unit-cell parameters a = 99.88, b = 99.88, c = 144.59 A, alpha = beta = gamma = 90 degrees . A full set of diffraction data were collected to 2.5 A resolution at 100 K using synchrotron radiation at Pohang beamline 4A. |
| SCZ Keywords | schizophrenia, schizophrenic |
| 3 | Psychopharmacology (Berl.) 2013 Mar 226: 177-88 |
| PMID | 23093381 |
| Title | Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment. |
| Abstract | Regulator of G-protein signaling (RGS) proteins, RGS4 and RGS10, may be involved in the pathophysiology of schizophrenia. RGS4 has attracted special interest since the reports of genetic association between SNPs in RGS4 and schizophrenia. However, there is no information about the subcellular distribution of RGS4 and RGS10 proteins in psychiatric disorders. Plasma membrane RGS4 and cytosolic RGS10 protein immunoreactivity in prefrontal cortex from schizophrenic subjects (n?=?25), non-diagnosed suicides (n?=?13), and control subjects (n?=?35), matched by age, gender, and postmortem delay, was analyzed by western blot. A second group of depressed subjects (n?=?25) and control subjects (n?=?25) was evaluated. The effect of the antipsychotic or antidepressant treatments was also assessed. No significant differences in plasma membrane RGS4 and cytosolic RGS10 protein expression were observed between schizophrenic subjects, non-diagnosed suicides, and control subjects. However, RGS4 immunoreactivity was significantly higher (??=?33?±?10 %, p?RGS10 proteins did not differ between depressed and matched control subjects. Expression of RGS4 and RGS10 proteins at their predominant subcellular location was studied in the postmortem brain of subjects with psychiatric disorders. The results suggest unaltered membrane RGS4 and cytosolic RGS10 proteins levels in schizophrenia and major depression. Antipsychotic treatment seems to increase membrane RGS4 immunoreactivity. Further studies are needed to elucidate RGS4 and RGS10 functional status. |
| SCZ Keywords | schizophrenia, schizophrenic |
| 4 | Psychopharmacology (Berl.) 2013 Mar 226: 177-88 |
| PMID | 23093381 |
| Title | Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment. |
| Abstract | Regulator of G-protein signaling (RGS) proteins, RGS4 and RGS10, may be involved in the pathophysiology of schizophrenia. RGS4 has attracted special interest since the reports of genetic association between SNPs in RGS4 and schizophrenia. However, there is no information about the subcellular distribution of RGS4 and RGS10 proteins in psychiatric disorders. Plasma membrane RGS4 and cytosolic RGS10 protein immunoreactivity in prefrontal cortex from schizophrenic subjects (n?=?25), non-diagnosed suicides (n?=?13), and control subjects (n?=?35), matched by age, gender, and postmortem delay, was analyzed by western blot. A second group of depressed subjects (n?=?25) and control subjects (n?=?25) was evaluated. The effect of the antipsychotic or antidepressant treatments was also assessed. No significant differences in plasma membrane RGS4 and cytosolic RGS10 protein expression were observed between schizophrenic subjects, non-diagnosed suicides, and control subjects. However, RGS4 immunoreactivity was significantly higher (??=?33?±?10 %, p?RGS10 proteins did not differ between depressed and matched control subjects. Expression of RGS4 and RGS10 proteins at their predominant subcellular location was studied in the postmortem brain of subjects with psychiatric disorders. The results suggest unaltered membrane RGS4 and cytosolic RGS10 proteins levels in schizophrenia and major depression. Antipsychotic treatment seems to increase membrane RGS4 immunoreactivity. Further studies are needed to elucidate RGS4 and RGS10 functional status. |
| SCZ Keywords | schizophrenia, schizophrenic |